anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new therapeutic agent for inflammatory diseases including septicemia.  &lt;P&gt;SOLUTION: A mouse is immunized with a human peripheral blood mononuclear cell fraction to thereby produce an antibody, and an examination is made on the cytokine production inhibition effect of the obtained antibody. As a result, an anti-CD36 antibody can be found, which can strongly inhibit the production of IFNγ by PBMC by itself. An examination is also made on the effect of the antibody on the production of other cytokines, and it is found that the anti-CD36 antibody ensures the inhibition of the production of typical inflammatory cytokines. It is also found that the anti-CD36 antibody has activity of promoting the production of an anti-inflammatory cytokine. The antibody enables the treatment of an inflammatory disease through the inhibition of the production of primary inflammatory cytokines or through the promotion of the production of anti-inflammatory cytokines.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an eucalyptus extract exhibiting an excellent hair restoration effect and a hair restorer containing the eucalyptus extract.  &lt;P&gt;SOLUTION: The extract of eucalyptus young leaves is obtained by extracting young leaves of Eucalyptus globulus with a solvent. The young leaves is the ones sprung out on branches germinated within 2 years. The solvent used for the solvent extract is a mixture of one kind, two kinds or more selected from among water, ethanol, propylene glycol, and 1, 3-butylene glycol. The hair restorer uses the extract of eucalyptus young leaves obtained by extracting young leaves of Eucalyptus globulus with the solvent as the effective ingredient. The hair restorer contains a blood circulation stimulator and hair follicle activator. The hair restorer contains 0.0005-5 mass% of the extract of eucalyptus young leaves as a solid.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE: To provide a cross linking agent-bonded carrier excellent in shelf life by providing a diol structure or polyol structure in the terminal area of the cross linking agent bonded to carrier protein, and prepare an immunogen in a short time by use of this cross linking agent-bonded carrier. CONSTITUTION: Bisepoxide is reacted with carrier protein as a cross linking agent to form an epoxidized carrier protein. The epoxy group in the terminal part which is not reacted with the carrier protein of the cross linking agent is changed to a stable diol structure. Thus, it can be stored for a long period. It is treated with periodic acid at the reaction with hapten to convert the diol group into an aldehyde group. After the excessive periodic acid is then removed, it is reacted with the hapten having an amino group to form a Schiff&#39;s base, whereby an immunogen can be easily formed.
Provided herein are systems and methods for optimizing a 3D model of an individual&#39;s teeth. A 3D dental model may be reconstructed from 3D parameters. A differentiable renderer may be used to derive a 2D rendering of the individual&#39;s dentition. 2D image(s) of an individual&#39;s dentition may be obtained, and features may be extracted from the 2D image(s). Image loss between the 2D rendering and the 2D image(s) can be derived, and back-propagation from the image loss can be used to calculate gradients of the loss to optimize the 3D parameters. A machine learning model can also be trained to predict a 3D dental model from 2D images of an individual&#39;s dentition.
334,898. Groves, W&#39;. W., (I. G. Farbenindustrie Akt.-Ges.). June 11, 1929. Hormones. - The hormones or active substances present in the, posterior lobe of the hypoplysis are extracted and separated into those which act on the uterus and those which increase the blood pressure. The fresh or dried gland is extracted with methyl or other alcohol containing hydrochloric sulphuric or other inorganic acid. The extract is precipitated either by neutralizing the acid by means of methyl alcohol containing ammonia or by addition of ether or other organic precipitant. The precipitate is dissolved in acidified alcohol and the solution is precipitated fractionally with acetone and ether, the first fractions containing more of the substances which act on the blood pressure- The filtrates containing the substances which act on the uterus are concentrated while feebly acid, shaken with water to form two layers, and the hormone obtained by distilling the alcohol from the aqueous layer and precipitating with petroleum ether. Alternatively the original extract may be precipitated first with acetone and then with ether.
Systems and methods for designing and implementing patient-specific surgical procedures and/or medical devices are disclosed. In some embodiments, a method includes receiving a patient data set of a patient. The patient data set is compared to a plurality of reference patient data sets, wherein each of the plurality of reference patient data sets is associated with a corresponding reference patient. A subset of the plurality of reference patient data sets is selected based, at least partly, on similarity to the patient data set and treatment outcome of the corresponding reference patient. Based on the selected subset, at least one surgical procedure or medical device design for treating the patient is generated. In some embodiments, the at least one surgical procedure or medical device design can be used to treat the patient&#39;s pelvic region and/or sacroiliac joint.
PROBLEM TO BE SOLVED: To provide a medicine information management system using non- contact IC tags for making it possible for pharmaceutical companies or pharmaceutical distribution companies to obtain, via communications lines, information on medicines consumed by medical facilities, and precisely administer medicines as prescribed. SOLUTION: Medicine identification data are stored in the non-contact IC tag and prescription data are stored in a medical record card. A plurality of communications terminals are installed at a pharmaceutical company, a pharmaceutical distribution company, and a hospital. Each of the communications terminals has an antenna for reading the medicine identification data of the IC tag, and a transmitting and receiving means for transmitting the medicine identification data to a server and for receiving information. The hospital&#39;s communications terminal has a reading means for reading medical record data, an antenna for reading the medicine identification data of the tag, and a collating and determining means for the data read by the reading means and the antenna. The server has a medicine information database.
Systems and methods for aiding individuals to complete tasks of daily living are provided. The situationally aware system comprises a controller, sensors, and effectors. The controller may include a program that describes a sequence of steps the user should perform to accomplish the task. In response to the information from the sensors and the user&#39;s compliance with the steps of the sequence, the controller instructs the effector(s) to relay at least one instructional cue to the user to aid in the performance of the task. The instructional cue may range from a simple blinking light, to detailed audio and/or visual instructions, to relaying a reward for the completion of the task. The instructional cue may also instruct the user to refrain from performing a task. The system is programmable, configurable, and may interface to the Internet.
Pregnancy in animals such as the pig usually does not continue to term when there are only a few embryos in the uterus. Currently available technology for maintaining pregnancy involves a series of hormone injections, and the failure rate is high. It has now been discovered that pregnancy can be maintained by complementing fertile embryos in the uterus with additional embryos that aren&#39;t expected to survive the full term of the pregnancy. Particularly suitable are parthenogenetic embryos, formed by activating and diploidizing unfertilized oocytes. The carrier embryos are engrafted into the uterus of a surrogate female, and the pregnancy continues to term without further intervention—even if the number of fertile embryos are below the minimum litter size. This provides valuable biological material that can be used for transplantation, the production of pharmaceuticals, and for agricultural use.
Nisoldipine is an extended release tablet and should be swallowed whole. Tablets should not be chewed, divided or crushed. Nisoldipine should be taken on an empty stomach (1 hour before or 2 hours after a meal). Grapefruit juice, which has been shown to increase significantly the bioavailability of nisoldipine and other dihydropyridine type calcium channel blockers, should not be taken with Nisoldipine. This product contains FD&amp;C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&amp;C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.
PROBLEM TO BE SOLVED: To obtain a new vascularization inhibitor having an activities to inhibit growth and migration of an endothelial cell of a human capillary vessel and to inhibit formation of lumen, and useful for prevention and treatment of rheumatic arthritis, etc., by including an imidazole derivative having a specific structure or its salt as an active ingredient. SOLUTION: This vascularization inhibitor includes an imidazole derivative of formula I [one of A and B is a group of formula II (R&lt;1&gt; is H, a halogen, etc.; R&lt;2&gt; and R&lt;3&gt; are each H, a lower alkoxy, etc.; R&lt;4&gt; and R&lt;5&gt; are each H or a 1-3C alkyl) and the other is a carbamoyl group] or its salt as an active ingredient. The compound of formula I is exemplified by (E)-5(4)-(3- methoxycinnamoylamino)imidazole-4(5)-carboxamide hydrogen chloride salt. The compound of formula I is, for example, obtained by reacting a cinnamic acid derivative of formula III (R&lt;10&gt; is H, a protected mono and lower alkyl substituted amine, etc.) with an aminoimidazole derivative of formula IV (one of P and Q is an amino group and the other is a carbamoyl group) in the presence of a base in an inert solvent.
PURPOSE:To provide a dental material compounded with a specific methacrylic acid ester dimer, having low odor and low irritation, giving a polymer having low water absorption and exhibiting a moderate glutinous time when used as a prosthetic material. CONSTITUTION:A methacrylic ester dimer of formula is compounded as an essential component in an amount of preferably &gt;=20wt.% (especially &gt;=30wt.%) to a dental material to be used as a prosthetic material, a composite resin, a dental crown resin, a sealant, an adhesive, etc., to obtain the objective material. Since the material has the above properties, it does not give uncomfortable feeling such as odor and mucosal irritation to the patient even by directly applying to the oral cavity. The cured product can be used over a long period because it has excellent durability (e.g. dimensional change, stability of strength and discoloration) even under extremely severe wet condition in the oral cavity. It can be safely and hygienically treated by dentists and dental mechanics to improve the working efficiency.
PURPOSE:To deposit and separate berberine alkaloid as an ionic salt, by treating a tissue piece or cell of a plant containing the berberine alkaloid with sulfuric acid and adding a salt exchange agent containing chlorine ion, sulfuric acid ion, etc., to the resultant extract solution. CONSTITUTION:A tissue piece or cell of a plant containing berberine alkaloid, e.g. goldthread or Amur cork, is dipped in a 0.2-0.5N aqueous solution of sulfuric acid for &gt;=1hr to give an extract solution. A salt exchange agent, preferably an aqueous solution of hydrochloric acid or nitric acid, containing chlorine ion and/or nitric acid ion is then added to the extract solution to convert the berberine alkaloid into a slightly soluble ionic salt at 10-30 deg.C deposit and separate the berberine alkaloid. EFFECT:The aimed substance is obtained in high purity and recovery ratio by the simple method in a few steps. USE:A medicine for intestinal disorder, remedy for bacterial intestinal diseases and yellowish dyes.
Novel compounds of the formula &lt;FORM:1104516/C2/1&gt; (where B is alkylene, alkarylene or arylene; R is C1- 5 alkyl, trihalomethyl-alkyl, cycloalkyl, aralkyl, aryloxy, arylthio, arylthioalkyl, aralkylthio or carboxyalkyl; R1 and R2 are H or C1- 5 alkyl or they may be joined to form a cycloalkyl ring of 5 or 6 nuclear carbon atoms; X is OH, C1- 5 alkoxy, or N(R3)2 where each R3 is H or C1- 5 alkyl; and X1 and X2 are H, halogen or C1- 5 alkyl, with the proviso that when R1 and R2 are both H and B is C1- 5 alkylene, or mononuclear arylene which may be C1- 5 alkyl substituted, R is not C1- 5 alkyl, cycloalkyl, mononuclear aryl-C1- 5 alkyl, mononuclear aryloxy, carboxy-C1- 5 alkyl, mononuclear arylthio, mononuclear arylthio-C1- 5 alkyl or trihalomethyl-C1- 5 alkyl) and salts thereof are prepared (1) for the free acids, by insertion of the group R.C.R1.R2.CO- into compounds of the above formula wherein X is OH not containing this group, by reaction with the appropriate acyl halide in the presence of a Friedel Craft catalyst, or by etherification of the corresponding naphthols already containing the R.C.R1.R2.CO- group and the optional X1 and X2 groups with the appropriate halo-acid ester hal-B-CO2X1 (X1 is a hydrocarbon group) in the presence of a base, and hydrolysing the resulting ester; and (2) for the salts, esters, amides, by standard procedures from the free acids.  Products wherein R is aralkyl and R2 is H may also be prepared by insertion of the aralkyl group into a compound containing an R1-CH2-CO-side chain by condensation with an araldehyde followed by hydrogenation of the arylalkenoyl compound thus obtained. Products wherein R is aryloxy, arylthioalkyl or aralkylthio may also be prepared from compounds containing a haloalkanoyl side chain and an appropriate phenol, thiophenol, or aralkylmercaptan in presence of a base.  Products containing a 5-alkyl substituent are difficult to prepare by methods (1) and (2) above and are prepared by reaction of a 5-alkanoyloxy-3,4-dihydro-1(2H)-naphthalenone with a Grignard reagent to give a 1-hydroxy-1-alkyl-1,2,3,4-tetrahydro-5-naphthol, etherification of this to the corresponding alkyl (5-hydroxy-5-alkyl-5,6,7,8-tetrahydro-1-naphthyloxy) alkanoate, dehydration to the corresponding alkyl (7,8-dihydro-5-alkyl-1-naphthyloxy) alkanoate, hydrogenation to the corresponding 5,6,7,8-tetrahydro compound, saponification to the free acid, reaction with an alkanoyl halide to yield a 4-alkanoyl-5 - alkyl - 5,6,7,8 - tetrahydro - 1 - naphthyloxy-alkanoic acid esterification and aromatization. A single example describes the preparation of [4 - (2 - methylbutyryl) - 1 - naphthyloxy]-acetic acid.  The naphthalene derivatives of the invention, which are stated to be diuretic or saluretic agents, may be made up into pharmaceutical compositions with or without other diuretics.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an aqueous ophthalmic composition thickened by a water-soluble macromolecular compound and having high viscosity stability in its long-term storage.  &lt;P&gt;SOLUTION: This ophthalmic composition is obtained by formulating (A) the thickened ophthalmic composition containing the water-soluble macromolecular compound with (B) at least one ingredient selected from dibutyl hydroxytoluene, butyl hydroxyanisole, ascorbic acid or a salt thereof and a sulfite. The thickened ophthalmic composition containing the water-soluble macromolecular compound is filled in a resin-made container and then sealed in a packaging body. The concentration of innert gas in a space formed between the container and the packaging body is regulated to be ≥50 vol%. Or, the container filled with the thickened ophthalmic composition containing the water-soluble macromolecular compound is sealed is the packaging body together with a deoxidation agent.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
FIELD: medicine, psychiatry. SUBSTANCE: method involves preliminary stage (patient state estimation), psychopharmacological stage (administration of magnesium sulfate with ketamine) followed by verbal action. The latter involves treatment in order to get indifferent behavior to alcohol in combination with simultaneous massage of superciliary arch region and epigastral region and/or plexus solaris that induces formation &#34;energetic parasite&#34; state in patient associated with negative sites of alcoholic existence followed by its elimination; at the terminal stage patient survival analysis is carried out at additional correction of neurotic symptoms in patient, for example, using reflexotherapy. Treatment involves 2-5 procedures at interval for 5-10 days. EFFECT: improved method of treatment. 6 cl
&lt;P&gt;PROBLEM TO BE SOLVED: To support data verification work after medical sales by using a data verification support server connected to an implementer terminal and a verifier terminal via a network.  &lt;P&gt;SOLUTION: The data verification support method supports data verification work after medical sales by using the data verification support server connected to the implementer terminal and the verifier terminal via the network. The implementer terminal displays a logic check result in a survey sheet input screen per medicine to be surveyed when patient information is inputted. The verifier terminal displays the logic check result and survey sheet registration information registered by the data verification support server. Resurvey inquiry request information or survey completion is supplied to the verification support server. The data verification support server supplies resurvey sheet information of a medicine to be resurveyed to the implementer terminal, and it manages version numbers of requests. A progress of data verification is supplied to the implementer terminal or the verifier terminal.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
FIELD: veterinary science. SUBSTANCE: invention relates to the preparation used for correction of immune system disorders and prophylaxis and treatment of animals with infectious and invasion diseases being in mammals of all species. The preparation &#34;Milon&#34; is the organogermanium derivative of pyridinediol of the composition C 15 H 27 N 3 O 6 Ge. Pharmacological effect of the preparation involves the broad spectrum of activities: immunomodulation (as the main), antiviral, anthelmintic and antibacterial. EFFECT: enhanced effectiveness of the preparation. 4 cl, 2 tbl, 8 ex
The present invention provides novel agents for specifically targeting and detecting or treating focal sites of infection or inflammation in a subject. The diagnostic agents of the invention rapidly localize at sites of infection or inflammation. In addition, the agents exhibit a relatively high target-to-background ratio and rapid clearance from the background and the target particular when administered as a bolus intravenously. Further, clinical pharmakonetic studies indicate that administration of colony stimulating factors in an amount effective for targeting would be relatively safe. The invention is based, at least in part, on the surprising finding that radiolabeled G-CSF effectively localizes to sites of infection. This empirical result is surprising, since the expression level of CSF receptors on cells has been found to be relatively low, compared to the expression level of other growth factor receptors on hematopoietic cells (Park et al., &#34;Hemapoietic Growth-Factor Receptors&#34; p. 39-75 in). Based on the cross-reactivity between CSFs and CSF receptors (Walker, F., and A.W. Burgess (1987) J. Cell. Physiol. 130:255-261), it is expected that other CSFs will also bind to sites of infection.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a composition, especially food and beverage that are safe to human, animals, etc., is continuously ingested and has excellent prevention and/or amelioration action on peptic ulcer.  &lt;P&gt;SOLUTION: The composition for preventing and/or ameliorating peptic ulcer comprises a sesamin. The composition contains 0.001-10 wt.% of a sesamin. An excellent peptic amelioration composition, especially food and beverage are obtained. The composition containing a sesamin is safely administered to human and animals. Consequently, the composition is continuously administered and is a composition for preventing and ameliorating peptic ulcer without causing a rebound.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
Compsn. to alleviate proliferative skin diseases contains a pharmacologically acceptable carrier and &gt;=1 cpd. of formula (I) or acid addn. salts: (where R = 1-4C alkyl or 3-6C cycloalkyl; and R1 = H, acetyl or propionyl). The compsn. can be used to treat e.g. psoriasis, atropical dermatitis, non-specific dermatitis, primary irritant contact dermatitis, allergic contact dermatitis, basal and squamous cell carcinomas of the skin, lamellar ichthyosis, non-malign keratosis, acne and dandruff in humans and atopical dermatitis and mange in domestic animals. Suitable oral doses are 2-30 mg taken 1-4 times daily, but higher doses for psoriasis are pref.
FIELD: veterinary science. SUBSTANCE: the suggested antipyretic composition includes paracetamol solution in low-molecular polyethylene glycol and/or polypropylene glycol, moreover, paracetamol is in the quantity of 15-25 weight%. Composition should be introduced either into drinking water for animals in the farm equipped with water-circulating system or into animals&#39; fodder due to spraying this composition on food granules. Antipyretic composition obtained is stable at storage, well soluble in cold water. EFFECT: higher efficiency. 9 cl, 3 tbl
All antioxidants must be in a reduced form to be therapeutically active. They are easily oxidized by air oxygen, pollutants, ozone, ferric ions abundant in drinking water, light and other oxidative intervention and become inactive. Stabilizers that have higher redox potentials than antioxidants protect them from oxidative damage. Catechins and their congeners are antioxidants, but their relative redox potentials as well as their qualification as stabilizers are not known until these experiments. These experiments show that catechins (3&#34;,4&#34;,5,7-pentahydroxyflavan) and their congeners (proanthocyandins, polyhydroxy flavans, polyhydroxyflavones, and polyphenols), and natural products containing them have higher redox potentials, thereby protecting antioxidants from oxidative inactivation. Stabilizer-added antioxidant formulations and products are the core of this invention to maintain the full activity of the antioxidants.
PROBLEM TO BE SOLVED: To obtain a skin cosmetic excellent in water resistance and stability, good in extensivity and having a refreshing touch by compounding an alkyl- modified carboxylvinylpolymer exhibiting water repellency and an organic silicone resin having a specific structure. SOLUTION: A skin cosmetic contains an alkyl-modified carboxyvinyl polymer and one or more kinds of organic silicone resins containing structural units of the formula (R&lt;1&gt; is a 1-6C hydrocarbon; n is 1.0-1.8) and having an average mol. wt. of 1500-10000. The organic silicone resin is preferably added in an amount of 0.05-50wt.% based on the whole amount of the skin cosmetic. The alkyl-modified carboxyvinyl polymer is preferably added in an amount of 0.01-10wt.% based on the whole amount of the skin cosmetic. The cosmetic can hold a skin roughnessimproving effect over a long time and further prevent its adhesion to contact articles.